Current Edition

COVID-19

Novavax, fashionably late to the COVID-19 vaccine party, could still reap $5B in 2022: analyst

After a winding path to a coronavirus vaccine launch that still hasn’t reached the U.S., Novavax’s program could be destined to reap billions of dollars …

Continue Reading →
biotech

Novavax finally submits its COVID-19 vaccine to the FDA. Is it too late?

It’s finally here: After a series of delays in the lead-up to Novavax’s COVID-19 vaccine filing with the FDA, the biotech has completed its emergency …

Continue Reading →
COVID-19

After Moderna contamination mess, Takeda strikes deal with Japan to supply Novavax COVID-19 vaccines

As Moderna faces questions about contaminants found in its COVID-19 vaccines in Japan, the company’s distribution partner in the country, Takeda, is moving forward on …

Continue Reading →